The upcoming session features a panel of experts from Clario—including Chief Medical Officer Todd Rudo and Cardiology lead Vic Patel—who will address the challenges of clinical trial design in the obesity and type 2 diabetes space. By shifting focus toward patient-reported outcomes, glucose monitoring, and advanced medical imaging, sponsors can better navigate the transition from early-phase dose selection to late-phase differentiation.
In section Releases
Refining Obesity Drug Trials Through Strategic Endpoint Selection
As the market for GLP-1 receptor agonists and dual-action therapies surges, drug developers face mounting pressure to prove clinical value beyond basic weight loss. A September 17 webinar hosted by Xtalks will examine how integrating precise endpoint strategies can sharpen efficacy data and streamline the path toward regulatory approval.
Effective endpoint selection remains critical for identifying safety signals early and building robust, regulator-ready evidence packages. Attendees will learn how to leverage these specialized technologies to reduce development uncertainty and ensure that emerging therapies stand out in an increasingly crowded pharmaceutical landscape. The live event is scheduled for 11am EDT on September 17, 2026, and provides a platform for industry professionals to align on best practices for data-driven decision-making.
Comments (0)
No comments yet. Be the first!